Calypso Biotech to be acquired by Novartis under a deal with a $250M upfront and potential $175M in milestones, with their lead antibody, CALY-002, targeting IL-15.
Novartis Pharma will purchase SanReno Therapeutics, enhancing its kidney treatment range. Following the acquisition, SanReno will join Novartis China, advancing clinical trials of two important IgA nephropathy treatments, atrasentan and BION-1301.
On January 8, 2024, Johnson & Johnson acquired Ambrx Biopharma for $2 billion to enhance its Antibody-Drug Conjugate (ADC) portfolio, including promising treatments like ARX517 for metastatic prostate cancer.
GSK Plc agreed to buy Aiolos Bio, Inc. for $1 billion, plus up to $400 million in milestones, gaining access to Aiolos’s leading candidate, AIO-001, a long-acting anti-TSLP monoclonal antibody.
Henlius Biotech and Sermonix Pharmaceuticals have formed a strategic alliance for the exclusive development, production, and commercialization of the investigational drug lasofoxifene in China.
Harbour Biomed and its subsidiary Nona Biosciences have entered an exclusive deal with Pfizer for the global development and commercialization of their anti-mesothelin ADC, HBM9033.
The CDE recently accepted Innovent Biologics and GenFleet Therapeutics' joint NDA for GF-105, prioritizing its review for advanced NSCLC patients with the KRAS G12C mutation after first-line therapy.